AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Nicole DeFeudis

Editor

AbbVie CEO Rob Michael said the company will invest $10 billion in the US over the next decade, as the threat of pharmaceutical-specific tariffs looms …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

New fund will pressure flailing biotechs, as investor frustration boils over

RFK Jr. touts CMS program testing new ways to pay for sickle cell disease treatment

Merck KGaA closes in on SpringWorks deal at $3.5B price point

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead